Insurance coverage and type of employment shape inequities in access to semaglutide

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity since the US Food & Drug Administration first approved semaglutide (brand name Ozempic/Wegovy) for weight loss in 2021. Approval of tirzepatide (brand name Mounjaro/Zepbound), an even more efficacious medication, soon followed in 2023.